Blood neurofilament light chain at the doorstep of clinical application
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published August 9, 2019.
Author Disclosures
- David Leppert, MD and
- Jens Kuhle, MD, PhD
- David Leppert, MD and
NONE
NONE
Travel cost reimbursement and speaker honoraria from Sanofi and Orion
NONE
NONE
NONE
David Leppert has been a Novartis employee until January 2019.
NONE
NONE
NONE
NONE
David leppert has been a Novartis employee until January 2019.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jens Kuhle, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Bayer AG (2) Biogen (3) Celgene (4) Genzyme (5) Merck (4) Novartis (5) Roche Pharma (Schweiz) AG
(1) Swiss National Research Foundation
NONE
(1) ECTRIMS Research Fellowship Programme (2) University of Basel (3) Swiss MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
- Correspondence
Dr. Kuhle jens.kuhle{at}usb.ch or Dr. Leppert david.leppert{at}unibas.ch
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MSSimon Thebault, Daniel R. Tessier, Hyunwoo Lee et al.Neurology: Neuroimmunology & Neuroinflammation, August 09, 2019 -
Clinical/Scientific Notes
NfL is a biomarker for adult-onset leukoencephalopathy with axonal spheroids and pigmented gliaStefanie N. Hayer, Ilona Krey, Christian Barro et al.Neurology, September 14, 2018 -
Article
Neurofilament light chainA prognostic biomarker in amyotrophic lateral sclerosisChing-Hua Lu, Corrie Macdonald-Wallis, Elizabeth Gray et al.Neurology, May 01, 2015 -
Article
Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MSSinah Engel, Michaela Friedrich, Muthuraman Muthuraman et al.Neurology: Neuroimmunology & Neuroinflammation, July 19, 2019